华兰生物：控股子公司收到药物临床试验批准通知书

Core Viewpoint - The company, Hualan Biological Engineering, announced that its subsidiary, Hualan Vaccine, has received approval from the National Medical Products Administration for clinical trials of a recombinant herpes zoster vaccine [1] Group 1: Product Details - The drug is classified as a Class 1.3 preventive biological product and is intended for the prevention of herpes zoster, not for the prevention of primary varicella [1] - The approval indicates that the vaccine meets the necessary requirements for drug registration and is recommended for clinical trial initiation [1]